CompletedNCT00337285
Long-term lisdexamfetamine treatment for adults with ADHD
About this title
Read the official source — NCT00337285Researchers studied Vyvanse (lisdexamfetamine dimesylate), NRP104 to find out how it affected ADHD symptoms in adults with ADHD.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
Researchers studied Vyvanse (lisdexamfetamine dimesylate), NRP104 to find out how it affected ADHD symptoms in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 349
- Sponsor
- New River Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00337285
- Official title
Show the full official title
A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · El Centro · Irvine
40 more locations
- Lafayette
- Rolling Hills Estate
- San Francisco
- Spring Valley
- Boulder
- New London
- Fort Myers
- Miami
- Orlando
- Tampa
- West Palm Beach
- Roswell
- Smyrna
- Overland Park
- Lutherville
- Rockville
- Cambridge
- Flint
- Rochester Hills
- Saint Charles
- Las Vegas
- Clementon
- New York
- Durham
- Raleigh
- Columbus
- Oklahoma City
- Portland
- Philadelphia
- Austin
- Bellaire
- Houston
- Lake Jackson
- Lubbock
- Burlington
- Woodstock
- Charlottesville
- Herndon
- Virginia Beach
- Seattle
Questions about this study
What did researchers investigate?
Researchers studied Vyvanse (lisdexamfetamine dimesylate), NRP104 to find out how it affected ADHD symptoms in adults with ADHD.
Who is behind this study?
The study sponsor is New River Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Vyvanse (lisdexamfetamine dimesylate), NRP104.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
